Younes A and Aggarwall BB |
Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. |
2003 |
Cancer |
pmid:12879461
|
Nawroth P et al. |
[Osteoporosis and cardiovascular disease--two sides of the same coin?]. |
2003 |
Med. Klin. (Munich) |
pmid:12928809
|
Hayashi S et al. |
Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha. |
2003 |
J. Immunol. |
pmid:14607912
|
Padigel UM et al. |
TRANCE-RANK costimulation is required for IL-12 production and the initiation of a Th1-type response to Leishmania major infection in CD40L-deficient mice. |
2003 |
J. Immunol. |
pmid:14607948
|
Terpos E et al. |
New insights into the pathophysiology and management of bone disease in multiple myeloma. |
2003 |
Br. J. Haematol. |
pmid:14632767
|
Zhang L et al. |
The role of calmodulin in the regulation of osteoclastogenesis. |
2003 |
Endocrinology |
pmid:12960067
|
Abrahamsen B et al. |
Effects of the natural and artificial menstrual cycle on the production of osteoprotegerin and the bone resorptive cytokines IL-1beta and IL-6. |
2003 |
Calcif. Tissue Int. |
pmid:12384814
|
Zhang J et al. |
Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. |
2003 |
Cancer Res. |
pmid:14633717
|
Chan BY et al. |
Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum. |
2003 |
Clin. Chem. |
pmid:14633883
|
Jung K et al. |
Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. |
2003 |
J. Urol. |
pmid:14634401
|
Kanatani M et al. |
Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity. |
2003 |
J. Cell. Physiol. |
pmid:12767054
|
Ha H et al. |
Membrane rafts play a crucial role in receptor activator of nuclear factor kappaB signaling and osteoclast function. |
2003 |
J. Biol. Chem. |
pmid:12637570
|
Ritchlin CT et al. |
Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. |
2003 |
J. Clin. Invest. |
pmid:12639988
|
Fujita D et al. |
Prostaglandin E2 induced the differentiation of osteoclasts in mouse osteoblast-depleted bone marrow cells. |
2003 |
Prostaglandins Leukot. Essent. Fatty Acids |
pmid:12711253
|
Katavić V et al. |
Increased bone mass is a part of the generalized lymphoproliferative disorder phenotype in the mouse. |
2003 |
J. Immunol. |
pmid:12538719
|
Nishimura K et al. |
Effects of irradiation on cementum matrix cytokins function during periodontal regeneration. |
2003 |
Hum. Cell |
pmid:15147042
|
Choi BK et al. |
Induction of osteoclastogenesis and matrix metalloproteinase expression by the lipooligosaccharide of Treponema denticola. |
2003 |
Infect. Immun. |
pmid:12496170
|
Liu D et al. |
Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction. |
2003 |
Int. J. Mol. Med. |
pmid:12469211
|
Crotti TN et al. |
Variability of RANKL and osteoprotegerin staining in synovial tissue from patients with active rheumatoid arthritis: quantification using color video image analysis. |
2003 |
J. Rheumatol. |
pmid:14677171
|
Walsh MC and Choi Y |
Biology of the TRANCE axis. |
2003 Jun-Aug |
Cytokine Growth Factor Rev. |
pmid:12787563
|
Smith BB et al. |
A toxicity profile of osteoprotegerin in the cynomolgus monkey. |
2003 Sep-Oct |
Int. J. Toxicol. |
pmid:14555415
|
Ogasawara T et al. |
In situ expression of RANKL, RANK, osteoprotegerin and cytokines in osteoclasts of rat periodontal tissue. |
2004 |
J. Periodont. Res. |
pmid:14687227
|
Blair HC and Athanasou NA |
Recent advances in osteoclast biology and pathological bone resorption. |
2004 |
Histol. Histopathol. |
pmid:14702187
|
Kumamoto H and Ooya K |
Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas. |
2004 |
J. Oral Pathol. Med. |
pmid:14675140
|
Crisafulli A et al. |
Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women. |
2004 |
J. Clin. Endocrinol. Metab. |
pmid:14715848
|
Onyia JE et al. |
Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption. |
2004 |
J. Pharmacol. Exp. Ther. |
pmid:14718597
|
Smith MD |
Comment on review on T cells in bone biology. |
2004 |
Rheumatology (Oxford) |
pmid:15448222
|
Boabaid F et al. |
Leucine-rich amelogenin peptide: a candidate signaling molecule during cementogenesis. |
2004 |
J. Periodontol. |
pmid:15455742
|
Schett G et al. |
Soluble RANKL and risk of nontraumatic fracture. |
2004 |
JAMA |
pmid:14996780
|
Tsuji K et al. |
Periodontal ligament cells under intermittent tensile stress regulate mRNA expression of osteoprotegerin and tissue inhibitor of matrix metalloprotease-1 and -2. |
2004 |
J. Bone Miner. Metab. |
pmid:14999519
|
Jørgensen HL et al. |
Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios. |
2004 |
J. Bone Miner. Metab. |
pmid:14999524
|
Kobayashi-Sakamoto M et al. |
NF-kappaB-dependent induction of osteoprotegerin by Porphyromonas gingivalis in endothelial cells. |
2004 |
Biochem. Biophys. Res. Commun. |
pmid:15013432
|
MacQuarrie RA et al. |
Wear-particle-induced osteoclast osteolysis: the role of particulates and mechanical strain. |
2004 |
J. Biomed. Mater. Res. Part B Appl. Biomater. |
pmid:15015218
|
Ishii T et al. |
Osteopontin as a positive regulator in the osteoclastogenesis of arthritis. |
2004 |
Biochem. Biophys. Res. Commun. |
pmid:15033472
|
Suda T and Miyaura C |
[Recent advance in basic research for osteoporosis]. |
2004 |
Nippon Rinsho |
pmid:15035090
|
Matsumoto T |
[Recent advances in the regulation of bone remodeling]. |
2004 |
Nippon Rinsho |
pmid:15035093
|
Okumura S et al. |
[Regulatory mechanism of osteoclast differentiation and function]. |
2004 |
Nippon Rinsho |
pmid:15035103
|
Udagawa N et al. |
[Possible role of RANKL in bone resorption]. |
2004 |
Nippon Rinsho |
pmid:15035104
|
Inoue D |
[OPG(osteoprotegerin)/OCIF(osteoclastogenesis inhibitory factor)]. |
2004 |
Nippon Rinsho |
pmid:15035105
|
Suzuki Y |
[Stimulator of bone resorption interleukin-1, interleukin-6 and gp-130 cytokine family]. |
2004 |
Nippon Rinsho |
pmid:15035106
|
Miyaura C |
[LPS]. |
2004 |
Nippon Rinsho |
pmid:15035108
|
Sattler AM et al. |
Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. |
2004 |
Calcif. Tissue Int. |
pmid:14523602
|
Bergh JJ et al. |
Osteoprotegerin expression and secretion are regulated by calcium influx through the L-type voltage-sensitive calcium channel. |
2004 |
Endocrinology |
pmid:14525906
|
Wise GE et al. |
Regulation of secretion of osteoprotegerin in rat dental follicle cells. |
2004 |
Eur. J. Oral Sci. |
pmid:15458504
|
Dai SM et al. |
Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha. |
2004 |
Ann. Rheum. Dis. |
pmid:15479886
|
Wang JC et al. |
Osteosclerosis in idiopathic myelofibrosis is related to the overproduction of osteoprotegerin (OPG). |
2004 |
Exp. Hematol. |
pmid:15504545
|
Fan X et al. |
Nitric oxide regulates receptor activator of nuclear factor-kappaB ligand and osteoprotegerin expression in bone marrow stromal cells. |
2004 |
Endocrinology |
pmid:14563699
|
Kondo T et al. |
1 alpha,25 dihydroxyvitamin D3 rapidly regulates the mouse osteoprotegerin gene through dual pathways. |
2004 |
J. Bone Miner. Res. |
pmid:15312241
|
Daroszewska A et al. |
Susceptibility to Paget's disease of bone is influenced by a common polymorphic variant of osteoprotegerin. |
2004 |
J. Bone Miner. Res. |
pmid:15312251
|
Liu JM et al. |
[The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75]. |
2004 |
Zhonghua Nei Ke Za Zhi |
pmid:15312444
|
Jacobson A et al. |
Vitamin A differentially regulates RANKL and OPG expression in human osteoblasts. |
2004 |
Biochem. Biophys. Res. Commun. |
pmid:15313187
|
Ishida M and Amano S |
Osteocalcin fragment in bone matrix enhances osteoclast maturation at a late stage of osteoclast differentiation. |
2004 |
J. Bone Miner. Metab. |
pmid:15316862
|
Sato T et al. |
Interleukin-11 as an osteoprotegerin-inducing factor in culture medium of blastic cells from a patient with acute megakaryocytic leukemia complicated with osteosclerosis. |
2004 |
Am. J. Hematol. |
pmid:15307108
|
Giuliani N et al. |
New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). |
2004 |
Exp. Hematol. |
pmid:15308315
|
Colucci S et al. |
T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. |
2004 |
Blood |
pmid:15308561
|
Miyazaki T et al. |
Changes in receptor activator of nuclear factor-kappaB, and its ligand, osteoprotegerin, bone-type alkaline phosphatase, and tartrate-resistant acid phosphatase in ovariectomized rats. |
2004 |
J. Cell. Biochem. |
pmid:15372622
|
Jeffcoate W |
Vascular calcification and osteolysis in diabetic neuropathy-is RANK-L the missing link? |
2004 |
Diabetologia |
pmid:15322748
|
Liu Z et al. |
Production of recombinant human osteoprotegrin from Trichoplusia ni cells and Bombyx mori larvae. |
2004 |
Protein Pept. Lett. |
pmid:15327363
|
Politou M et al. |
Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). |
2004 |
Br. J. Haematol. |
pmid:15327520
|
Xiao XH et al. |
[Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro]. |
2004 |
Zhonghua Yi Xue Za Zhi |
pmid:15730627
|
Tiranathanagul S et al. |
Actinobacillus actinomycetemcomitans lipopolysaccharide activates matrix metalloproteinase-2 and increases receptor activator of nuclear factor-kappaB ligand expression in human periodontal ligament cells. |
2004 |
J. Periodontol. |
pmid:15732867
|
Bord S et al. |
Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen. |
2004 |
Br. J. Haematol. |
pmid:15238146
|
Buxton EC et al. |
Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). |
2004 |
J. Clin. Endocrinol. Metab. |
pmid:15240611
|
Kochanowska I et al. |
Influence of osteoprotegerin (OPG) on resorption of heterotopically induced ossicle. |
2004 |
Cell Tissue Bank |
pmid:15241009
|
Corso A et al. |
Osteoprotegerin serum levels in multiple myeloma and MGUS patients compared with age- and sex-matched healthy controls. |
2004 |
Leukemia |
pmid:15241438
|
Harada M et al. |
Concentration of osteoprotegerin (OPG) in peritoneal fluid is increased in women with endometriosis. |
2004 |
Hum. Reprod. |
pmid:15242994
|
Kang HS et al. |
Receptor activator of nuclear factor-kappaB is induced by a rottlerin-sensitive and p38 MAP kinase-dependent pathway during monocyte differentiation. |
2004 |
Mol. Cells |
pmid:15232218
|
Kazama JJ |
Osteoprotegerin and bone mineral metabolism in renal failure. |
2004 |
Curr. Opin. Nephrol. Hypertens. |
pmid:15199291
|
Walsh NC and Gravallese EM |
Bone loss in inflammatory arthritis: mechanisms and treatment strategies. |
2004 |
Curr Opin Rheumatol |
pmid:15201606
|
Terpos E et al. |
Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. |
2004 |
Leukemia |
pmid:15215875
|
Brändström H et al. |
A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA). |
2004 |
Blood Press. |
pmid:15223723
|
Wilson SE et al. |
RANK, RANKL, OPG, and M-CSF expression in stromal cells during corneal wound healing. |
2004 |
Invest. Ophthalmol. Vis. Sci. |
pmid:15223796
|
Pioletti DP and Kottelat A |
The influence of wear particles in the expression of osteoclastogenesis factors by osteoblasts. |
2004 |
Biomaterials |
pmid:15172492
|
Livshits G et al. |
Genetic influences on the circulating cytokines involved in osteoclastogenesis. |
2004 |
J. Med. Genet. |
pmid:15173242
|
Ueland T et al. |
Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. |
2004 |
J. Am. Coll. Cardiol. |
pmid:15542278
|
Demer LL and Abedin M |
Skeleton key to vascular disease. |
2004 |
J. Am. Coll. Cardiol. |
pmid:15542279
|
Vidal K et al. |
Osteoprotegerin production by human intestinal epithelial cells: a potential regulator of mucosal immune responses. |
2004 |
Am. J. Physiol. Gastrointest. Liver Physiol. |
pmid:15521102
|
Lee CK et al. |
Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. |
2004 |
Arthritis Rheum. |
pmid:15593184
|
Grzegorzewska AE and MÅ‚ot M |
Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease. |
2004 |
Rocz. Akad. Med. Bialymst. |
pmid:15631341
|
Grzegorzewska AE and MÅ‚ot M |
Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones. |
2004 |
Rocz. Akad. Med. Bialymst. |
pmid:15631342
|
Yeung RS |
The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss. |
2004 |
J. Rheumatol. |
pmid:15124240
|
Masi L et al. |
Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury? |
2004 |
J. Rheumatol. |
pmid:15124262
|
Eaton CL et al. |
Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. |
2004 |
Prostate |
pmid:15042606
|
Nitta K et al. |
Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. |
2004 |
Nephrol. Dial. Transplant. |
pmid:15128884
|
O' Gradaigh D et al. |
Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts. |
2004 |
Ann. Rheum. Dis. |
pmid:15020327
|
Milstead JR et al. |
Spaceflight and hindlimb suspension disuse models in mice. |
2004 |
Biomed Sci Instrum |
pmid:15133943
|
Karst M et al. |
Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation. |
2004 |
J. Cell. Physiol. |
pmid:15137062
|
Emanuele E et al. |
Plasma osteoprotegerin as a biochemical marker for vascular dementia and Alzheimer's disease. |
2004 |
Int. J. Mol. Med. |
pmid:15138623
|
Kyrtsonis MC et al. |
Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. |
2004 |
Eur. J. Haematol. |
pmid:15089762
|
Miao D et al. |
Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice. |
2004 |
Endocrinology |
pmid:15090463
|
Haynes DR et al. |
Regulation of osteoclast activity in peri-implant tissues. |
2004 |
Biomaterials |
pmid:15109848
|
Ito S and Hata T |
Crystal structure of RANK ligand involved in bone metabolism. |
2004 |
Vitam. Horm. |
pmid:15110169
|
Hao C et al. |
Modulation of TRAIL signaling complex. |
2004 |
Vitam. Horm. |
pmid:15110173
|
Herrmann M and Herrmann W |
The assessment of bone metabolism in female elite endurance athletes by biochemical bone markers. |
2004 |
Clin. Chem. Lab. Med. |
pmid:15576300
|
Jono S |
[Risk factors of atherosclerosis in end-stage renal disease patients]. |
2004 |
Clin Calcium |
pmid:15576949
|
Shimizu M and Tamura T |
[Regulation of bone mineralization by parathyroid hormone]. |
2004 |
Clin Calcium |
pmid:15577058
|
Ogata H et al. |
[Prophylaxis and treatment of adynamic bone]. |
2004 |
Clin Calcium |
pmid:15577107
|
Altun A et al. |
Decreased serum osteoprotegerin levels in patients with cardiac syndrome X. |
2004 |
J. Endocrinol. Invest. |
pmid:15648548
|
Buzi F et al. |
Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis. |
2004 |
Clin. Endocrinol. (Oxf) |
pmid:14678293
|
Cheng X et al. |
Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo. |
2004 |
J. Biol. Chem. |
pmid:14679212
|